BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).
It’s nearly always bad news when pharma companies provide an “update” about a trial – and the statement today from Novartis about its asthma drug fevipiprant must make bleak reading for all
Finland’s Forendo Pharma has signed a deal with Novartis aimed at identifying novel drugs for treatment of chronic liver diseases, with the potentially lucrative fatty liver disease known a
